Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavorixafor + Ibrutinib in Waldenstrom's Macroglobulinemia
NCT04274738Phase 1Completed
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Apr 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of mavorixafor in Waldenstrom macroglobulinemia (WM), sponsored by X4 Pharmaceuticals, Inc. Primary endpoints: Number of Participants With Dose-Limiting Toxicities, Percent Change From Baseline in Immunoglobulin M (IgM) at Cycle 3 and 4 more. Started Apr 2020; status: completed.
02
Drugs
mavorixafor
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT04274738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274738.